# Aurora Cannabis Inc: overview ACB · Nasdaq · CIK 1683541 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Mar 31 Pages: [Overview](/companies/acb.md) · [Financials](/companies/acb/financials.md) · [Filings](/companies/acb/filings.md) · [Insiders](/companies/acb/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q4 FY2022 (2022-06-30) | period not labelled (2024-06-30) | period not labelled (2024-09-30) | period not labelled (2024-12-31) | Q4 FY2025 (2025-03-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | not reported | [0.10](/filings/0001683541-25-000008.md) | not reported | not reported | not reported | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL Gross profit: ifrs-full:GrossProfit. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: ifrs-full:ProfitLossFromOperatingActivities. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: ifrs-full:ProfitLossAttributableToOwnersOfParent; Net income: ifrs-full:ProfitLoss. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure. - Diluted EPS. XBRL Diluted EPS: ifrs-full:DilutedEarningsLossPerShare. - Free cash flow (operating cash flow − capital expenditure). XBRL not reported. ## Last five fiscal years | Line item | Unit | FY2020 (2020-06-30) | FY2021 (2021-06-30) | FY2022 (2022-06-30) | FY2024 (2024-03-31) | FY2025 (2025-03-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [269](/filings/0001683541-21-000003.md) | [245](/filings/0001683541-22-000002.md) | [221](/filings/0001683541-23-000007.md) | [270](/filings/0001683541-25-000008.md) | [343](/filings/0001683541-25-000008.md) | | Gross margin | % | [(7.4%)](/filings/0001683541-21-000003.md) | [(8.8%)](/filings/0001683541-22-000002.md) | [9.6%](/filings/0001683541-23-000007.md) | [48.9%](/filings/0001683541-25-000008.md) | [54.6%](/filings/0001683541-25-000008.md) | | Operating margin | % | [(173.3%)](/filings/0001683541-21-000003.md) | [(115.3%)](/filings/0001683541-22-000002.md) | [(104.6%)](/filings/0001683541-23-000007.md) | [(16.7%)](/filings/0001683541-25-000008.md) | [1.4%](/filings/0001683541-25-000008.md) | | Net margin | % | [(1221.7%)](/filings/0001683541-21-000003.md) | [(282.2%)](/filings/0001683541-22-000002.md) | [(776.0%)](/filings/0001683541-22-000002.md) | [(25.7%)](/filings/0001683541-25-000008.md) | [0.5%](/filings/0001683541-25-000008.md) | | Diluted EPS | $ per share | not reported | [(4.10)](/filings/0001683541-22-000002.md) | [(7.99)](/filings/0001683541-22-000002.md) | [(1.52)](/filings/0001683541-25-000008.md) | [0.04](/filings/0001683541-25-000008.md) | | Free cash flow | $m | not reported | [(264)](/filings/0001683541-22-000002.md) | [(142)](/filings/0001683541-23-000007.md) | not reported | not reported | - Revenue. XBRL Revenue: ifrs-full:Revenue; Revenue: ifrs-full:RevenueFromContractsWithCustomers. - Gross margin (gross profit / revenue). XBRL Gross profit: ifrs-full:GrossProfit; Revenue: ifrs-full:Revenue; Revenue: ifrs-full:RevenueFromContractsWithCustomers. - Operating margin (operating income / revenue). XBRL Operating income: ifrs-full:ProfitLossFromOperatingActivities; Revenue: ifrs-full:Revenue; Revenue: ifrs-full:RevenueFromContractsWithCustomers. - Net margin (net income / revenue). XBRL Net income: ifrs-full:ProfitLossAttributableToOwnersOfParent; Revenue: ifrs-full:Revenue; Net income: ifrs-full:ProfitLoss; Revenue: ifrs-full:RevenueFromContractsWithCustomers. - Diluted EPS. XBRL Diluted EPS: ifrs-full:DilutedEarningsLossPerShare. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: ifrs-full:CashFlowsFromUsedInOperatingActivities; Capital expenditure: ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/acb/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $3.8m | 1,350,837 | | Added +294,619 | | [Tidal Investments LLC](/funds/1600064.md) | 2026-06-30 | $3.5m | 1,264,494 | | Added +14,827 | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $2.2m | 784,955 | | Added +26,774 | | [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $807.7k | 289,500 | Call | Reduced −48,900 | | [NATIONAL BANK OF CANADA /FI/](/funds/926171.md) | 2026-06-30 | $672.5k | 241,055 | | Reduced −30,235 | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $671.5k | 240,698 | | Reduced −18,357 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $523.7k | 187,700 | Put | Added +55,100 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $513.6k | 184,100 | Call | Reduced −40,000 | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $495.4k | 177,561 | | Added +25,293 | | [AdvisorShares Investments LLC](/funds/1425930.md) | 2026-06-30 | $477.4k | 171,110 | | Unchanged | ## Recent filings [All 428 filings](/companies/acb/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-29 | 07:18 ET | [6-K](/filings/0001104659-26-119872.md) | Report of a foreign private issuer, period 2026-10-29 | 0001104659-26-119872 | | 2026-10-26 | 09:30 ET | [6-K](/filings/0001279569-26-001004.md) | Report of a foreign private issuer, period 2026-10-26 | 0001279569-26-001004 | | 2026-10-14 | 16:18 ET | [6-K](/filings/0001279569-26-000974.md) | Report of a foreign private issuer, period 2026-10-14 | 0001279569-26-000974 | | 2026-10-08 | 08:16 ET | [6-K](/filings/0001279569-26-000960.md) | Report of a foreign private issuer, period 2026-10-08 | 0001279569-26-000960 | | 2026-10-07 | 17:35 ET | [6-K](/filings/0001279569-26-000955.md) | Report of a foreign private issuer, period 2026-10-06 | 0001279569-26-000955 | | 2026-10-06 | 18:41 ET | [6-K](/filings/0001279569-26-000950.md) | Report of a foreign private issuer, period 2026-10-05 | 0001279569-26-000950 | | 2026-09-24 | 19:38 ET | [6-K](/filings/0001279569-26-000915.md) | Report of a foreign private issuer, period 2026-09-23 | 0001279569-26-000915 | | 2026-09-16 | 07:24 ET | [6-K](/filings/0001279569-26-000887.md) | Report of a foreign private issuer, period 2026-09-16 | 0001279569-26-000887 | | 2026-09-14 | 14:28 ET | [6-K](/filings/0001279569-26-000881.md) | Report of a foreign private issuer, period 2026-09-14 | 0001279569-26-000881 | | 2026-09-09 | 07:39 ET | [6-K](/filings/0001279569-26-000865.md) | Report of a foreign private issuer, period 2026-09-09 | 0001279569-26-000865 | ## Latest annual report [Form 40-F for the fiscal year ended Mar 31, 2026](/filings/0001628280-26-042364.md), filed Jun 11, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1683541 - Tickers: ACB - Exchange: Nasdaq - SIC code: 2833 Medicinal Chemicals & Botanical Products - State of incorporation: A1 - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 07:19 ET. No prices; not investment advice.